Building a network with U.S. investors to establish a global market bridgehead for Korean biotechnology 스피드 바카라 사이트
[by Ji, Yong Jun] Dt&CRO announced on June 24 that it hosted a corporate introduction (IR) networking event on June 17 (local time) in Boston, aimed at facilitating connections between Korean biotech companies and global investors. The event was held in collaboration with Radyus Research, a U.S.-based consulting firm specializing in new drug development.
Co-hosted by Dt&CRO and Radyus Research, the event was held in conjunction with the ‘2025 Bio International Convention (BIO USA)’ in Boston, USA, with the aim of fostering partnerships between 12 promising Korean biotech 스피드 바카라 사이트 and 31 global investors, including representatives from the United States. The initiative sought to move beyond basic corporate introductions by providing a platform for domestic biotech 스피드 바카라 사이트 to engage directly with local investors in the U.S., receive constructive feedback, and explore potential avenues for collaboration through open dialogue.
“This event offered a broad spectrum of partnership opportunities, ranging from 스피드 바카라 사이트 in the early stages of R&D to those on the verge of entering clinical trials, through investor-tailored networking sessions,” an official who participated in the event remarked.
A total of twelve Korean biotech 스피드 바카라 사이트 took part in the event, including siRNAgen Therapeutics, 3H Bio, CNCure, Astrogen, AulBio, iNTherapeutics, ApitBio, Autotelic Bio, OmniaMed, Immuse Therapeutics, ImmunAbs, and Q Genetics.
“Recently, interest in Korean biotech 스피드 바카라 사이트 developing next-generation technologies, such as cell gene therapy (CGT), messenger ribonucleic acid (mRNA), and treatments for rare diseases, has been growing in the U.S. market,” a Dt&CRO official stated. “This event served as a meaningful opportunity to directly showcase the technological prowess and potential of Korean biotech to global investors and to establish a foundation for strategic collaboration.”
Choi Jae-kyoung, CFO of 3H Bio, who attended the event, said, “It is encouraging that a link has been established between Korean biotech 스피드 바카라 사이트 and international investment 스피드 바카라 사이트 during a challenging period for the domestic biotech industry,” adding, “One-on-one customized meetings and ongoing networking are essential.”
Since the onset of the COVID-19 pandemic, the global biotechnology industry has witnessed an unprecedented influx of investment, driven by heightened recognition of its technology-driven growth potential and the evolving treatment paradigm. In particular, global venture capital firms (VCs), primarily based in the United States, are actively pursuing partnerships with 스피드 바카라 사이트 in Asia that possess strong clinical development capabilities. As a result, there is a growing demand for localization strategies and tailored IR approaches specifically designed for Korean biotech firms.
The company particularly noted that the event extended beyond basic networking, serving as an integrated platform that connected practical development strategies throughout the entire novel drug development cycle. This included guidance on U.S. Food and Drug Administration (FDA) pre-Investigational New Drug (pre-IND) and IND strategies, non-clinical toxicity testing, and global regulatory consulting.
“The participation of numerous overseas investment firms and diverse experts in the biotechnology industry was a positive signal, reflecting the growing recognition and interest in Korea’s pharmaceutical and biotechnology sectors,” stated Woo Jung-hoon, CEO of BW Biomed, who attended the event as an advisory member of Q Genetics. “I hope this networking platform continues to expand, enabling Korean 스피드 바카라 사이트 to engage more actively in global markets and ultimately leading to tangible investment opportunities.”
The Korean Consulate General in Boston also participated in the event, hosting a session to encourage Korean biotech 스피드 바카라 사이트. “The networking event between Korean biotech 스피드 바카라 사이트 and U.S.-based investors, organized by Dt&CRO and Radyus Research in conjunction with BIO USA, holds practical meaning as it provides a valuable bridgehead for domestic biotech 스피드 바카라 사이트 to enter the U.S. market. It is a remarkable event that demonstrates our 스피드 바카라 사이트 are now functioning as true players by actively engaging with and leveraging the U.S. life science industry ecosystem,” expressed Boston Consul General Kim Jae-hui.
“Through the 스피드 바카라 사이트’ confident and assertive presentation of their outstanding technologies to U.S. investors, I witnessed their aspirations and vision to take on a larger role in the U.S. biotech market,” Kim further commented. “Although entering the U.S. biotech market presents many challenges, I am confident that the passion demonstrated by these biotech 스피드 바카라 사이트, along with support provided by organizations like Dt&CRO, will lead to meaningful outcomes. The Consulate General, along with relevant government agencies, will continue to support the success of our 스피드 바카라 사이트.”
Dt&CRO is a GLP (Good Laboratory Practices) certified testing organization that supports early-stage new drug development 스피드 바카라 사이트 in generating non-clinical and clinical data. Radyus Research, its U.S.-based partner, offers practical regulatory and investment strategies, drawing on its collaborative experience with global pharmaceutical firms such as GlaxoSmithKline (GSK) and Roivant.
“This U.S. networking event marks the first example of a platform strategy aimed at facilitating the global expansion of Korean biotech 스피드 바카라 사이트,” a Dt&CRO Group official said. “We plan to evolve this initiative into a long-term cooperation model, with future efforts focused on establishing it as a regular, recurring program.”
